ישראל - עברית - Ministry of Health

eli lilly israel ltd - insulin lispro; insulin lispro protamine - תרחיף להזרקה - insulin lispro 50 %; insulin lispro protamine 50 % - insulin lispro - insulin lispro - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

ישראל - עברית - Ministry of Health

eli lilly israel ltd - insulin lispro; insulin lispro as protamine - תרחיף להזרקה - insulin lispro 25 %; insulin lispro as protamine 75 % - insulin lispro - insulin lispro - humalog mix 25 kwikpen is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

ישראל - עברית - Ministry of Health

eli lilly israel ltd - necitumumab - תרכיז להכנת תמיסה לאינפוזיה - necitumumab 16 mg / 1 ml - necitumumab

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - fluoxetine as hydrochloride - קפסולות - fluoxetine as hydrochloride 20 mg - fluoxetine

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine 300 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine as pamoate monohydrate 405 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated.

ישראל - עברית - Ministry of Health

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated..

ישראל - עברית - Ministry of Health

eli lilly israel ltd - gemcitabine as hydrochloride - אבקה מיובשת בהקפאה להכנת תרכיז לאינפוזיה - gemcitabine as hydrochloride 200 mg/vial - pyrimidine analogues - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.